Search Videos and More
Showing 1 - 12 of 12 results
Podcast
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
Video
Use of Melphalan Flufenamide Plus Dexamethasone for Multiple Myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, discusses the background and findings of his study on the use of melphalan flufenamide in combination with dexamethasone for the treatment of patients with multiple myeloma.
News
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in Immunotherapy
Despite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
Video
Study of SACI-IO for Triple Negative Metastatic Breast Cancer
Filipa Lynce, MD, provides an overview of a study at Dana-Farber Cancer Institute testing the safety and efficacy of sacituzumab govitecan (Trodelvy) with or without pembrolizumab (Keytruda) for patients with PD-L1-negative, triple-negative metastatic breast cancer.
News
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant
An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
News
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients
The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
News
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval
The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.
News
Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures
Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer.
News
CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
News
Targeted Therapy for Children with Leukemia Can Provide Substantial Benefit, Study Finds
Testing tumor tissue for genetic alterations that can be targeted by drugs, a mainstay of treatment in a variety of cancers, can benefit many children with leukemia, investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center report in a new study. In some cases, such therapy can be lifesaving.
Video
Dana-Farber Research Looks at Blood Test to Detect Cancer
Dana-Farber’s Deborah Schrag, MD, MPH, is leading the Pathfinder Study, a study that looks at a simple blood test and evaluates it to see if it could detect multiple cancer types at the earliest and most treatable stages.
Video
Myeloma Patients Covid-19: How to Keep Myeloma Care Safe During the Pandemic
Nikhil Munshi, MD, discusses Covid-19 and Myeloma, the understanding the disease, how to make the treatments safer all while being aware of Covid-19 protocols.